

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

**AMGEN INC., IMMUNEX CORPORATION, AMGEN
MANUFACTURING, LIMITED,**
Plaintiffs-Appellants

v.

**GAIL MIZNER, in her official capacity as Chair of
the Colorado Prescription Drug Affordability Re-
view Board, SAMI DIAB, in his official capacity as a
member of the Colorado Prescription Drug Afford-
ability Review Board, AMARYLIS GUTIERREZ, in
her official capacity as a member of the Colorado
Prescription Drug Affordability Review Board,
CATHERINE HARSHBARGER, in her official ca-
pacity as a member of the Colorado Prescription
Drug Affordability Review Board, JAMES JUSTIN
VANDENBERG, in his official capacity as a member
of the Colorado Prescription Drug Affordability Re-
view Board, MICHAEL CONWAY, in his official ca-
pacity as Commissioner of the Colorado Division of
Insurance, PHILIP WEISER, in his official capacity
as Attorney General of the State of Colorado,**
Defendants-Appellees

2025-1641

2 AMGEN INC. v. COLORADO PRES. DRUG AFFORDABILITY REVIEW
BOARD

Appeal from the United States District Court for the District of Colorado in No. 1:24-cv-00810-NYW-SBP, Judge Nina Y. Wang.

O R D E R

The parties submit a joint stipulation to voluntarily dismiss this appeal without prejudice pursuant to Federal Rule of Appellate Procedure 42(b), with each side to bear its own costs.

This court generally does not specify whether a dismissal of an appeal is with or without prejudice.

Upon consideration thereof,

IT IS ORDERED THAT:

- (1) The appeal is dismissed.
- (2) Each side shall bear its own costs.

FOR THE COURT



February 2, 2026
Date

Jarrett B. Perlow
Clerk of Court

ISSUED AS A MANDATE: February 2, 2026